INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Stuttgart
18.09.26 | 21:55
1,640 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,610 | 1,700 | 19.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Innate Pharma Extends Cash Runway Through Q1 2028 As Sobi Partnership Advances Lacutamab Into Phase 3 | 1 | pulse2.com | ||
| Do | Innate Pharma SA H1 Loss Drops | 1 | RTTNews | ||
| Do | Innate Pharma übertrifft Q2-Prognosen, doch die Aktie gibt nach | - | Investing.com Deutsch | ||
| Do | Innate Pharma H1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| Do | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Do | Innate Pharma gives H1 results | 3 | Seeking Alpha | ||
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| Do | Innate Pharma SA: Innate Pharma Reports First Half 2026 Business Update and Financial Results | 425 | Business Wire | New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing... ► Artikel lesen | |
| Mi | Innate Pharma closes Sobi partnership, receives $75m upfront | 2 | Investing.com | ||
| Mi | Innate Pharma SA: Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions | 326 | Business Wire | The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD... ► Artikel lesen | |
| Mo | Innate Pharma: Fokussierte Pipeline und entscheidende Studiendaten im Blick | 1 | Investing.com Deutsch | ||
| 10.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | Innate Pharma SA: Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update | 425 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at... ► Artikel lesen | |
| 02.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.09. | Innate Pharma SA: Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | 413 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 19.08. | Innate Pharma SA - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 14.08. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast | 541 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00... ► Artikel lesen | |
| 14.08. | Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares | 830 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced... ► Artikel lesen | |
| 13.08. | Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares | 836 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced... ► Artikel lesen | |
| 10.08. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.08. | Innate Pharma plans phase 3 trial, names new medical officer | 1 | Investing.com |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 1,095 | +0,46 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| TME PHARMA | 0,118 | +7,69 % | TME Pharma NV: TME Pharma CEO Message | TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel... ► Artikel lesen | |
| CANSINO BIOLOGICS | 2,880 | 0,00 % | CANSINOBIO (06185): 2026 INTERIM REPORT | ||
| KARYOPHARM | 1,540 | -5,52 % | Karyopharm Therapeutics Inc.: Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis | - sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested -
NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc.... ► Artikel lesen | |
| ADICET BIO | 7,900 | -1,86 % | Adicet Bio, Inc. - 8-K, Current Report | ||
| MEREO BIOPHARMA | 0,234 | -12,69 % | Cantor Fitzgerald reiterates Mereo BioPharma stock Overweight rating at $3 | ||
| ANNOVIS BIO | 0,977 | -2,88 % | Annovis Bio Inc.: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results | Pivotal Phase 3 Alzheimer's disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson's disease (PD) open-label extension (OLE) study has enrolled... ► Artikel lesen | |
| INTEGRA LIFESCIENCES | 13,200 | 0,00 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Second Quarter 2026 Financial Results | PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 86,00 | +1,18 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan | -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 3,710 | +0,27 % | Neuphoria Therapeutics Inc. - 10-K, Annual Report | ||
| RECCE PHARMACEUTICALS | 0,180 | +1,69 % | RECCE PHARMACEUTICALS LTD: 2026 Annual General Meeting | ||
| MABION | 1,714 | -0,23 % | ODDIFACT: Oddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune Thrombocytopenia | FDA grants Type B pre-IND meeting, enabling critical alignment with the Agency on the development strategy for RTX-NPOddifact and Mabion aim to bring rituximab's well-established activity in ITP... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,640 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.